A Multicountry, Multicentre, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after First Line Osimertinib in patients with advanced and Metastatic NSCLC EGFRm in the GCC Region

Trial Identifier: D5161R00045
Sponsor: AstraZeneca
NCTID:: NCT06039683
Start Date: December 2022
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Kuwait Kuwait, Kuwait
Qatar Doha, Qatar
Saudi Arabia Dammam, Saudi Arabia
Saudi Arabia Jeddah, Saudi Arabia
Saudi Arabia Riyadh, Saudi Arabia
United Arab Emirates Abu Dhabi, United Arab Emirates
United Arab Emirates Al Ain, United Arab Emirates
United Arab Emirates Dubai, United Arab Emirates